Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Impact · against what's priced in

The regulatory submission for an Eylea 8mg biosimilar validates the bear case for Regeneron's revenue erosion, though the impact is muted as the market already prices in significant Eylea declines. For Bayer, this represents a new competitive headwind for their shared product line.

REGN−0.20: Challenges what's priced in
The price assumes: The Leerink bear case valuing the stock 18% lower, which assumes Eylea revenue erosion accelerates

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

What matters in this story

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

What matters in this story

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

How each ticker is affected

Track these names every morning.

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

ROSEN, A LONGSTANDING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

What matters in this story

Next reads from the same story arc

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

What matters in this story

Next reads from the same story arc

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

How each ticker is affected

Track these names every morning.

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

ROSEN, A LONGSTANDING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit